Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, vol.384, pp.164-172, 2014. ,
Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes, Cancer Res, vol.73, pp.6-06, 2013. ,
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy, Journal of Clinical Oncology, vol.25, pp.4414-4422, 2007. ,
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrencefree Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL, Radiology, vol.279, pp.44-55, 2016. ,
, Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, 2017.
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/ 150012; ACRIN 6657), Ann Surg Oncol, vol.21, p.24788555, 2014. ,
Staging of Breast Cancer in the Neoadjuvant Setting, Cancer Res, vol.68, pp.6477-6481, 2008. ,
The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment, JAMA Oncol, vol.2, pp.929-936, 2016. ,
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration, Ann. Oncol, vol.26, pp.1280-1291, 2015. ,
Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer, Ann. Oncol, vol.28, pp.2233-2240, 2017. ,
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J. Clin. Oncol, vol.17, pp.1474-1481, 1999. ,
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J. Clin. Oncol, vol.25, pp.118-145, 2007. ,
mice: Multivariate Imputation by Chained Equations in R, Journal of Statistical Software, vol.45, pp.1-67, 2011. ,
, R Development Core Team. R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, 2009.
Reproducibility of Residual Cancer Burden For Prognostic Assessment of Breast Cancer After Neoadjuvant Chemotherapy, Mod Pathol, vol.28, pp.913-920, 2015. ,
Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL, 2017. ,
, ACRIN 6657), vol.165, pp.181-191
Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer, Hum. Pathol, vol.45, pp.249-258, 2014. ,
Pathologic Response and Long-Term Follow-up in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Comparison Between Classifications and Their Practical Application, Archives of Pathology & Laboratory Medicine, vol.137, pp.1074-1082, 2013. ,
Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy, Clin Nucl Med, vol.39, pp.882-886, 2014. ,
Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients, Ann. Oncol, vol.24, pp.655-661, 2013. ,
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy, Ann. Oncol, vol.26, pp.75-80, 2015. ,
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype, J. Clin. Oncol, vol.35, pp.1049-1060, 2017. ,
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy, New England Journal of Medicine, vol.376, pp.2147-2159, 2017. ,
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer, N. Engl. J. Med, vol.380, pp.617-628, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02464524
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis, SABCS Abstract, pp.5-6, 2019. ,
Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin. Cancer Res, vol.11, pp.5678-5685, 2005. ,
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J. Clin. Oncol, vol.30, pp.1796-1804, 2012. ,
Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer, JCO, vol.28, pp.4111-4119, 2010. ,
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma, Breast Cancer Res. Treat, vol.169, p.29374852, 2018. ,
Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy, Clin Cancer Res clincanres, vol.3017, 2018. ,
Breast Cancer Immunotherapy: Facts and Hopes, Clin Cancer Res, vol.24, pp.511-520, 2018. ,
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors, Clin Cancer Res, vol.22, pp.1499-1509, 2016. ,
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling, Clin Cancer Res, vol.22, pp.5729-5737, 2016. ,
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2, JCO, vol.35, pp.506-506, 2017. ,
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells, Clin Cancer Res, vol.16, pp.3485-3494, 2010. ,